Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will release its fourth-quarter financial results, after the closing bell, on Monday, Feb. 10, 2025.

Analysts expect the Boston, Massachusetts-based company to report quarterly earnings at $4.02 per share, down from $4.20 per share in the year-ago period. Vertex Pharmaceuticals projects quarterly revenue of $2.78 billion, compared to $2.52 billion a year earlier, according to data from Benzinga Pro.

On Jan. 30, Vertex Pharmaceuticals announced it secured FDA approval for JOURNAVX. Also, the company announced a reimbursement agreement with NHS England for eligible sickle cell disease patients to access CASGEVY.

Vertex Pharmaceuticals shares fell 2.5% to close at $469.32 on Friday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Rating page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.

• HC Wainwright & Co. analyst Andrew Fein maintained a Buy rating and raised the price target from $535 to $550 on Jan. 31, 2025. This analyst has an accuracy rate of 61%.
• Wells Fargo analyst Mohit Bansal downgraded the stock from Overweight to Equal-Weight with a price target of $460 on Jan. 30, 2025. This analyst has an accuracy rate of 73%.
• Truist Securities analyst Joon Lee maintained a Buy rating and lowered the price target from $550 to $460 on Dec. 23, 2024. This analyst has an accuracy rate of 76%.
• JP Morgan analyst Jessica Fye maintained an Overweight rating and cut the price target from $503 to $500 on Dec. 23, 2024. This analyst has an accuracy rate of 63%.
• BMO Capital analyst Even Seigerman maintained an Outperform rating and cut the price target from $566 to $520 on Dec. 20, 2024. This analyst has an accuracy rate of 62%.

Considering buying VRTX stock? Here’s what analysts think:

Read This Next:

• Jim Cramer Likes This Utilities Stock: ‘I Think You’ve Got A Good One’